Logo image
Back
Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus
Journal article   Open access   Peer reviewed

Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus

Irwin Goldstein, LeRoy A Jones, Laurence H Belkoff, Gary S Karlin, Charles H Bowden, Craig A Peterson, Brenda A Trask and Wesley W Day
Mayo Clinic proceedings, v 87(9), pp 843-852
01 Sep 2012
DOI: https://doi.org/10.1016/j.mayocp.2012.06.016
PMID: 22857780
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1016/j.mayocp.2012.06.016View
Published, Version of Record (VoR) Open

Abstract

Diabetes Mellitus Double-Blind Method Erectile Dysfunction - drug therapy Humans Least-Squares Analysis Male Middle Aged Penile Erection - drug effects Placebos Prospective Studies Pyrimidines - therapeutic use Treatment Outcome
To prospectively assess the safety and effectiveness of the investigational phosphodiesterase 5 inhibitor avanafil to treat erectile dysfunction in men with diabetes mellitus. This 12-week, multicenter, double-blind, placebo-controlled study conducted between December 15, 2008, and February 11, 2010, randomized 390 men with diabetes and erectile dysfunction 1:1:1 to receive avanafil, 100 mg (n=129), avanafil, 200 mg (n=131), or placebo (n=130). Coprimary end points assessed changes in the percentage of sexual attempts in which men were able to maintain an erection of sufficient duration to have successful intercourse (Sexual Encounter Profile [SEP] 3), percentage of sexual attempts in which men were able to insert the penis into the partner's vagina (SEP 2), and International Index of Erectile Function erectile function domain score. Compared with placebo, least-squares mean change from baseline to study end in SEP 3, SEP 2, and International Index of Erectile Function erectile function domain score were significantly improved with both avanafil, 100 mg (P≤.002), and avanafil, 200 mg (P<.001). Additional analyses indicated that successful intercourse could be initiated in 15 minutes or less through more than 6 hours after avanafil dosing. Adverse events most commonly reported with avanafil treatment were headache, nasopharyngitis, flushing, and sinus congestion. Avanafil was safe and effective for treating erectile dysfunction in men with diabetes and was effective as early as 15 minutes and more than 6 hours after dosing. The adverse events seen with avanafil were similar to those seen with other phosphodiesterase 5 inhibitors. clinicaltrials.gov Identifier NCT00809471.

Metrics

4 Record Views
61 citations in Web of Science
83 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#5 Gender Equality
#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Urology & Nephrology
Logo image